- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to our latest study, the global Drug-Resistant Tuberculosis Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Drug-Resistant Tuberculosis Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Drug-Resistant Tuberculosis Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Drug-Resistant Tuberculosis Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drug-Resistant Tuberculosis Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drug-Resistant Tuberculosis Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Novartis AG, Endo International plc, CMP Pharma and STI Pharma LLC, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Drug-Resistant Tuberculosis Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others
Market segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Market segment by players, this report covers
Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Drug-Resistant Tuberculosis Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drug-Resistant Tuberculosis Treatment, with revenue, gross margin and global market share of Drug-Resistant Tuberculosis Treatment from 2018 to 2023.
Chapter 3, the Drug-Resistant Tuberculosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Drug-Resistant Tuberculosis Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Drug-Resistant Tuberculosis Treatment.
Chapter 13, to describe Drug-Resistant Tuberculosis Treatment research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Drug-Resistant Tuberculosis Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Drug-Resistant Tuberculosis Treatment by Type
1.3.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2022
1.3.3 First-Line Anti-TB Drugs
1.3.4 Second-Line Anti-TB Drugs
1.3.5 Others
1.4 Global Drug-Resistant Tuberculosis Treatment Market by Application
1.4.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacy
1.4.3 Online Pharmacy
1.4.4 Retail Pharmacy
1.4.5 Others
1.5 Global Drug-Resistant Tuberculosis Treatment Market Size & Forecast
1.6 Global Drug-Resistant Tuberculosis Treatment Market Size and Forecast by Region
1.6.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Drug-Resistant Tuberculosis Treatment Market Size by Region, (2018-2029)
1.6.3 North America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
2.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis AG Recent Developments and Future Plans
2.3 Endo International plc
2.3.1 Endo International plc Details
2.3.2 Endo International plc Major Business
2.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Endo International plc Recent Developments and Future Plans
2.4 CMP Pharma
2.4.1 CMP Pharma Details
2.4.2 CMP Pharma Major Business
2.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
2.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 CMP Pharma Recent Developments and Future Plans
2.5 STI Pharma LLC
2.5.1 STI Pharma LLC Details
2.5.2 STI Pharma LLC Major Business
2.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 STI Pharma LLC Recent Developments and Future Plans
2.6 Akorn Incorporated
2.6.1 Akorn Incorporated Details
2.6.2 Akorn Incorporated Major Business
2.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
2.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Akorn Incorporated Recent Developments and Future Plans
2.7 Lupin
2.7.1 Lupin Details
2.7.2 Lupin Major Business
2.7.3 Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
2.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Lupin Recent Developments and Future Plans
2.8 Johnson & Johnson Services Inc.
2.8.1 Johnson & Johnson Services Inc. Details
2.8.2 Johnson & Johnson Services Inc. Major Business
2.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Johnson & Johnson Services Inc. Recent Developments and Future Plans
2.9 Macleods Pharmaceuticals Ltd
2.9.1 Macleods Pharmaceuticals Ltd Details
2.9.2 Macleods Pharmaceuticals Ltd Major Business
2.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
2.10 Pfizer Inc
2.10.1 Pfizer Inc Details
2.10.2 Pfizer Inc Major Business
2.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Inc Recent Developments and Future Plans
2.11 Hikma Pharmaceuticals PLC
2.11.1 Hikma Pharmaceuticals PLC Details
2.11.2 Hikma Pharmaceuticals PLC Major Business
2.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
2.12 Lannett
2.12.1 Lannett Details
2.12.2 Lannett Major Business
2.12.3 Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
2.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Lannett Recent Developments and Future Plans
2.13 Mylan N.V.
2.13.1 Mylan N.V. Details
2.13.2 Mylan N.V. Major Business
2.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Mylan N.V. Recent Developments and Future Plans
2.14 Teva Pharmaceutical Industries Ltd
2.14.1 Teva Pharmaceutical Industries Ltd Details
2.14.2 Teva Pharmaceutical Industries Ltd Major Business
2.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.15 Fresenius Kabi AG
2.15.1 Fresenius Kabi AG Details
2.15.2 Fresenius Kabi AG Major Business
2.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Fresenius Kabi AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Drug-Resistant Tuberculosis Treatment by Company Revenue
3.2.2 Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2022
3.2.3 Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2022
3.3 Drug-Resistant Tuberculosis Treatment Market: Overall Company Footprint Analysis
3.3.1 Drug-Resistant Tuberculosis Treatment Market: Region Footprint
3.3.2 Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
3.3.3 Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Application (2024-2029)
6 North America
6.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
6.2 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
6.3.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
7.2 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
7.3.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
7.3.3 France Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region
8.3.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2018-2029)
8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8.3.5 India Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
9 South America
9.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
9.2 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
9.3 South America Drug-Resistant Tuberculosis Treatment Market Size by Country
9.3.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country
10.3.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Drug-Resistant Tuberculosis Treatment Market Drivers
11.2 Drug-Resistant Tuberculosis Treatment Market Restraints
11.3 Drug-Resistant Tuberculosis Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Drug-Resistant Tuberculosis Treatment Industry Chain
12.2 Drug-Resistant Tuberculosis Treatment Upstream Analysis
12.3 Drug-Resistant Tuberculosis Treatment Midstream Analysis
12.4 Drug-Resistant Tuberculosis Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 8. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Novartis AG Company Information, Head Office, and Major Competitors
Table 11. Novartis AG Major Business
Table 12. Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 13. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis AG Recent Developments and Future Plans
Table 15. Endo International plc Company Information, Head Office, and Major Competitors
Table 16. Endo International plc Major Business
Table 17. Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 18. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Endo International plc Recent Developments and Future Plans
Table 20. CMP Pharma Company Information, Head Office, and Major Competitors
Table 21. CMP Pharma Major Business
Table 22. CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 23. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. CMP Pharma Recent Developments and Future Plans
Table 25. STI Pharma LLC Company Information, Head Office, and Major Competitors
Table 26. STI Pharma LLC Major Business
Table 27. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 28. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. STI Pharma LLC Recent Developments and Future Plans
Table 30. Akorn Incorporated Company Information, Head Office, and Major Competitors
Table 31. Akorn Incorporated Major Business
Table 32. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 33. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Akorn Incorporated Recent Developments and Future Plans
Table 35. Lupin Company Information, Head Office, and Major Competitors
Table 36. Lupin Major Business
Table 37. Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 38. Lupin Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Lupin Recent Developments and Future Plans
Table 40. Johnson & Johnson Services Inc. Company Information, Head Office, and Major Competitors
Table 41. Johnson & Johnson Services Inc. Major Business
Table 42. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 43. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Johnson & Johnson Services Inc. Recent Developments and Future Plans
Table 45. Macleods Pharmaceuticals Ltd Company Information, Head Office, and Major Competitors
Table 46. Macleods Pharmaceuticals Ltd Major Business
Table 47. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 48. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
Table 50. Pfizer Inc Company Information, Head Office, and Major Competitors
Table 51. Pfizer Inc Major Business
Table 52. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 53. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Pfizer Inc Recent Developments and Future Plans
Table 55. Hikma Pharmaceuticals PLC Company Information, Head Office, and Major Competitors
Table 56. Hikma Pharmaceuticals PLC Major Business
Table 57. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 58. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Hikma Pharmaceuticals PLC Recent Developments and Future Plans
Table 60. Lannett Company Information, Head Office, and Major Competitors
Table 61. Lannett Major Business
Table 62. Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 63. Lannett Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Lannett Recent Developments and Future Plans
Table 65. Mylan N.V. Company Information, Head Office, and Major Competitors
Table 66. Mylan N.V. Major Business
Table 67. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 68. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Mylan N.V. Recent Developments and Future Plans
Table 70. Teva Pharmaceutical Industries Ltd Company Information, Head Office, and Major Competitors
Table 71. Teva Pharmaceutical Industries Ltd Major Business
Table 72. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 73. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Table 75. Fresenius Kabi AG Company Information, Head Office, and Major Competitors
Table 76. Fresenius Kabi AG Major Business
Table 77. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 78. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Fresenius Kabi AG Recent Developments and Future Plans
Table 80. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Players (2018-2023)
Table 81. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players (2018-2023)
Table 82. Breakdown of Drug-Resistant Tuberculosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Drug-Resistant Tuberculosis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Drug-Resistant Tuberculosis Treatment Players
Table 85. Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
Table 86. Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
Table 87. Drug-Resistant Tuberculosis Treatment New Market Entrants and Barriers to Market Entry
Table 88. Drug-Resistant Tuberculosis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2018-2023)
Table 91. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Type (2024-2029)
Table 92. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023)
Table 93. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Application (2024-2029)
Table 94. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Drug-Resistant Tuberculosis Treatment Raw Material
Table 125. Key Suppliers of Drug-Resistant Tuberculosis Treatment Raw Materials
List of Figures
Figure 1. Drug-Resistant Tuberculosis Treatment Picture
Figure 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2022
Figure 4. First-Line Anti-TB Drugs
Figure 5. Second-Line Anti-TB Drugs
Figure 6. Others
Figure 7. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application in 2022
Figure 9. Hospital Pharmacy Picture
Figure 10. Online Pharmacy Picture
Figure 11. Retail Pharmacy Picture
Figure 12. Others Picture
Figure 13. Global Drug-Resistant Tuberculosis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Drug-Resistant Tuberculosis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region in 2022
Figure 18. North America Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players in 2022
Figure 24. Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Drug-Resistant Tuberculosis Treatment Market Share in 2022
Figure 26. Global Top 6 Players Drug-Resistant Tuberculosis Treatment Market Share in 2022
Figure 27. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2018-2023)
Figure 28. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Type (2024-2029)
Figure 29. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Application (2018-2023)
Figure 30. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Application (2024-2029)
Figure 31. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. France Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 48. China Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. India Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Drug-Resistant Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. Drug-Resistant Tuberculosis Treatment Market Drivers
Figure 66. Drug-Resistant Tuberculosis Treatment Market Restraints
Figure 67. Drug-Resistant Tuberculosis Treatment Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Drug-Resistant Tuberculosis Treatment in 2022
Figure 70. Manufacturing Process Analysis of Drug-Resistant Tuberculosis Treatment
Figure 71. Drug-Resistant Tuberculosis Treatment Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
